Developing The World’s First Medical Device
Therapy for Acute Pancreatitis
Developing The World’s First Device Therapy
for Acute Pancreatitis
Chill-AP Pivotal Study launching early 2026 based on completion of successful First in Human Study
Arctx Medical is focused on developing innovative medical device therapies to improve outcomes for patients suffering from Acute Pancreatitis
Non-Surgical. Minimally Invasive.
The Human Costs of Acute Pancreatitis
3rd Leading
Gastrointestinal discharge diagnosis in the US
1M+ Hospital Days
Annually in the US
> 1 Month
Length of stay for 20-25% of patients
30% Mortality
In severe cases
$3B+ Annually
US health care costs and rising
High Morbidity
Even “Mild Acute Pancreatitis” is associated with significant morbidity